Citigroup

Citigroup’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Citigroup’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-57,000	Closed	-$1.27M	–	5796
2025 Q1	$1.27M	Hold	57,000	–	–	﹤0.01%	3082
2024 Q4	$1.13M	Buy	+57,000	New	+$1.3M	﹤0.01%	3270
2023 Q4	–	Sell	-30,000	Closed	-$521K	–	5793
2023 Q3	$521K	Sell	30,000 -30,000	-50%	-$505K	﹤0.01%	3034
2023 Q2	$845K	Sell	60,000 -40,000	-40%	-$535K	﹤0.01%	2973
2023 Q1	$1.08M	Sell	100,000 -5,000	-5%	-$65.9K	﹤0.01%	2484
2022 Q4	$1.57M	Buy	105,000 +70,000	+200%	+$1.02M	﹤0.01%	2232
2022 Q3	$449K	Buy	+35,000	New	+$399K	﹤0.01%	3321

Other funds holding KNSA

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return